Laboratorios Farmaceuticos Rovi (ROVI) CMD 2025 summary

Strategic direction and growth plans

• Targeting 1.5x–1.8x operating revenue growth by 2030 (to €1.15–1.3bn), with CDMO revenue expected to double to ~€700m and specialty pharma to see low single-digit growth, led by OkediⓇ.

• Focused on expanding CDMO capacity, including new filling lines, cartridges, autoinjectors, and pens, aiming for global leadership in complex injectables.

• Specialty pharma growth driven by international launches of OkediⓇ (Risperidone ISM®), new in-licensing agreements, and M&A to complement the portfolio.

• R&D pipeline includes Letrozole SIE and quarterly Risperidone, both entering Phase III trials in late 2025, leveraging ISM® technology.

• ESG strategy underpins operations, with a 2023–2025 plan focused on sustainability, supply chain responsibility, and R&D partnerships, and improved ratings under board supervision.

Financial guidance and performance

• 2024 operating revenue reached €763.7m, with CDMO at €336.2m and specialty pharma at €427.5m; 2025 guidance anticipates a mid-single-digit decrease before growth resumes.

• EBITDA pre-R&D for 2024 was €233.2m; targeted to grow 2.5x–2.8x by 2030, reaching €583–653m.

• Annual average R&D expenses projected at €40–60m for 2025–2030, up from €25.8m in 2024, with front-loaded costs for trial setup and recruitment.

• Maintains a strong balance sheet with net debt of €85.1m (0.4x ND/EBITDA), strong cash conversion (>70%), and a recurring dividend policy (35% payout of 2024 net profit).

• Capital allocation prioritizes capacity expansion, R&D, and shareholder returns, with no major M&A planned.

CDMO business evolution and outlook

• CDMO revenues grew from €92m in 2020 to €336m in 2024, with a target of ~€700m by 2030, supported by tripling capacity by 2026.

• Four fully invested manufacturing plants in Spain, with 12 aseptic filling lines expected by 2026 and flexible capacity for PFS, vials, and cartridges.

• Long-term contracts with over 30 blue-chip customers, including a 10-year Moderna deal and a new agreement for 100m PFS, provide revenue visibility.

• Strategic investments of €85m (2020–2024) and further CAPEX planned to address market shortages and demand for high-value injectables.

• Utilization rates expected to rise to 70–75% by 2030 as new lines become operational and market share increases from competitor exits.